Inactive Instrument

FUREN Group Pharmaceutical Co.,Ltd.

600781

CNE000000NM4

Furen Pharmaceutical Group Industry Co. Ltd. Announces Earnings Results for the Nine Months of 2018

October 24, 2018

Furen Pharmaceutical Group Industry Co. Ltd. announced earnings results for the nine months of 2018. For the period, basic earnings per share were CNY 1.17. Weighted average return on net assets was 14.87%.

Latest news about FUREN Group Pharmaceutical Co.,Ltd.

FUREN Group Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-30	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-29	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-30	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-29	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-29	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-30	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-28	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	20-06-19	CI
FUREN Group Pharmaceutical Co., Ltd. Appoints Zhu Wenliang as General Manager	20-06-11	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-29	CI
FUREN Group Pharmaceutical Co., Ltd. Elects Huang Dianying as Independent Director	20-01-07	CI
FUREN Group Pharmaceutical Co., Ltd.(SHSE:600781) dropped from Shanghai Stock Exchange Health Care Sector Index	19-12-13	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019	19-10-30	CI
Furen Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-30	CI
Shanghai Furen Industrial Co., Ltd Announces Cash Dividend for the Year 2018, Payable on July 22, 2019	19-07-14	CI
FUREN Group Pharmaceutical Co., Ltd.(SHSE:600781) added to Shanghai Stock Exchange Health Care Sector Index	19-06-25	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter 2019	19-04-28	CI
FUREN Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Year 2018	19-04-18	CI
Furen Pharmaceutical Group Industry Co., Ltd. Provides Earnings Guidance for the Year 2018	19-01-27	CI
FUREN Group Pharmaceutical Co., Ltd. cancelled the transaction announced on December 20, 2015	18-12-20	CI
Furen Pharmaceutical Group Industry Co. Ltd. Announces Earnings Results for the Nine Months of 2018	18-10-24	CI

Chart FUREN Group Pharmaceutical Co.,Ltd.

Duration

Period

Chart FUREN Group Pharmaceutical Co.,Ltd.

More charts

Company Profile

FUREN Group Pharmaceutical Co., Ltd., formerly Furen Pharmaceutical Group Industry Co., Ltd., is a China-based company principally engaged in the manufacturing, wholesale and retail of pharmaceuticals. The Company's principal business is the manufacture of proprietary Chinese medicines, including capsules, tablets, granules, gels, injections, suspensions, drops, syrups and others. The Company mainly distributes its products in the domestic market.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+32.36%	695B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	361B
MERCK & CO., INC.	+19.46%	330B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.85%	239B
NOVARTIS AG	+8.13%	204B
ROCHE HOLDING AG	-7.48%	198B
AMGEN INC.	+8.62%	168B

Other Pharmaceuticals